![Alain Horvais](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Alain Horvais first degree
Entity | Entity type | Industry | |
---|---|---|---|
Kurma Partners SA
![]() Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.
17
| Holding Company | Investment Managers | 17 |
FeetMe SAS
![]() FeetMe SAS Electronic Equipment/InstrumentsElectronic Technology FeetMe SAS develops insoles that map foot pressure in real time for diabetic patients. Its insoles are made of pressure sensors that allow patients and doctors to visualize a detailed pressure map of the feet, as well as provide warning to patients if a change in the plantar pressure is detected. The company was founded by Julien Mercier and Alexis Mathieu in 2013 and is headquartered in Versailles, France.
4
| Holding Company | Electronic Equipment/Instruments | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Alain Horvais via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
INSEAD | College/University | Doctorate Degree Masters Business Admin Masters Business Admin | |
ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
TXCELL | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Stilla Technologies SA
![]() Stilla Technologies SA Miscellaneous Commercial ServicesCommercial Services Stilla Technologies SA operates as a biotechnology company that focuses on the development genetic tests. It provides crystal digital PCR, a next-generation technology for absolute quantification of nucleic acids. The company was founded by Remi Dangla, Etienne Fradet and Clement Gay in 2013 and is headquartered in Villejuif, France. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
GENOCEA BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Horama SA
![]() Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
Eurazeo Investment Manager - EIM SA
![]() Eurazeo Investment Manager - EIM SA Investment ManagersFinance Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA. | Investment Managers | Investment Committee Member Private Equity Investor | |
SAFE ORTHOPAEDICS SA | Medical Specialties | Director/Board Member Director/Board Member | |
Step Pharma SAS
![]() Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Argobio SAS
![]() Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research. | Miscellaneous Commercial Services | President Chairman | |
TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member | |
INTEGRAGEN | Medical/Nursing Services | Director/Board Member Director/Board Member | |
THERADIAG | Medical Specialties | Director/Board Member Director/Board Member | |
Dyncaure SAS
![]() Dyncaure SAS Pharmaceuticals: MajorHealth Technology Dyncaure SAS manufactures non-therapeutic products. The private company is based in Anzin, France. | Pharmaceuticals: Major | Chairman | |
Aveni SA
![]() Aveni SA Chemicals: Major DiversifiedProcess Industries Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France. | Chemicals: Major Diversified | Director/Board Member | |
CELLNOVO | Medical Specialties | Director/Board Member | |
Tc Land Expression SA
![]() Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Miscellaneous Commercial Services | Director/Board Member | |
Domain Therapeutics SA
![]() Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Biotechnology | Director/Board Member | |
IMPLANET SA | Medical Specialties | Director/Board Member | |
AlchiMedics SA
![]() AlchiMedics SA Chemicals: Major DiversifiedProcess Industries AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France. | Chemicals: Major Diversified | Director/Board Member | |
BonitaSoft SA
![]() BonitaSoft SA Packaged SoftwareTechnology Services BonitaSoft SA develops open source software. It also provides open source business process management solutions. The firm's product, Bonita open solution, is an open source BPM solution that designs, develops, executes, and monitors business processes; Bonita Studio, a BPM notation solution for drawing processes graphically; and Bonita execution engine with Bonita open solution for integrating new services or BPM standards as they emerge. The company was founded by Rodrigue Le Gall, Charles Souillard, and Miguel Valdes-Faura in 2001 and is headquartered in Boulogne, France. | Packaged Software | Director/Board Member | |
ESSEC Business School | College/University | Graduate Degree | |
Convertigo SA
![]() Convertigo SA Packaged SoftwareTechnology Services Convertigo SAS provides Internet related software. It delivers a secured and scalable disruptive all-in-one solution, integrating rapid cross platform mobile development tools and a powerful MBaaS covering challenging backend enablement, featuring a middleware optimized for mobility. The company was founded by Olivier Picciotto and Jean-Michel Cohen in 1994 and is headquartered in Orsay, France. | Packaged Software | Director/Board Member | |
CYTOO SA
![]() CYTOO SA Medical SpecialtiesHealth Technology CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France. | Medical Specialties | Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
EKINOPS | Telecommunications Equipment | Director/Board Member | |
EVE SA
![]() EVE SA Computer PeripheralsElectronic Technology EVE SA provides electrical installation work on public roads. The company was founded in April 2000 and is headquartered in Paris, France. | Computer Peripherals | Director/Board Member | |
ENYO Pharma SA
![]() ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member | |
CDC Entreprises Innovation
![]() CDC Entreprises Innovation Financial ConglomeratesFinance CDC Entreprises Innovation provides venture capital services. It invests in information technology, communication, life sciences and semi-conductor industries. The company is headquartered in France. | Financial Conglomerates | Corporate Officer/Principal | |
Mutabilis SA
![]() Mutabilis SA Pharmaceuticals: MajorHealth Technology Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France. | Pharmaceuticals: Major | Director/Board Member | |
Finovelec | Corporate Officer/Principal | ||
Pharvaris GmbH
![]() Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member | |
STAT-Dx Life SL
![]() STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member | |
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member | |
Imcheck Therapeutics SAS
![]() Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Flamingo Therapeutics BV
![]() Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Director/Board Member | |
Nova School of Business & Economics | College/University | Graduate Degree | |
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
AgroParisTech | College/University | Graduate Degree |
Statistics
International
France | 37 |
Netherlands | 6 |
Belgium | 3 |
Denmark | 3 |
United States | 2 |
Sectoral
Health Technology | 29 |
Consumer Services | 6 |
Commercial Services | 6 |
Finance | 4 |
Health Services | 3 |
Operational
Director/Board Member | 146 |
Chairman | 32 |
Corporate Officer/Principal | 26 |
Private Equity Investor | 24 |
Independent Dir/Board Member | 17 |
Most connected contacts
Insiders | |
---|---|
Philippe Peltier | 45 |
Philippe Chambon | 31 |
Russell Greig | 31 |
Rémi Droller | 29 |
Anthony Adam Rosenberg | 23 |
Laurent Arthaud | 21 |
Thierry Laugel | 18 |
Vanessa Malier | 10 |
Peter Neubeck | 10 |
Brian Holzer | 8 |
Anne Osdoit | 8 |
Jean-François Rivassou | 5 |
Amanda Gett Chaperot | 5 |
Benjamin Belot | 5 |
Philippe Gallone | 4 |
- Stock Market
- Insiders
- Alain Horvais
- Company connections